Arcera Life Sciences, a life sciences company headquartered in Abu Dhabi and established by sovereign investor ADQ, has signed a Memorandum of Understanding with Shanghai Fosun Pharmaceutical Group Co., Ltd. (600196.SH; 02196.HK) to establish a long-term strategic framework spanning regional and global licensing, frontier technology incubation, and neurodegenerative diseases licensing, with a specific focus on Alzheimer’s disease programs. The China UAE pharma partnership is structured around three operational pillars and is aligned with Abu Dhabi’s Healthcare Life Sciences Vision 2030 and the broader Comprehensive Strategic Partnership between China and the UAE. No specific drug candidates are named in the MoU, and financial terms were not disclosed.
Under the first pillar, the collaboration will focus on identifying licensing opportunities for Fosun Pharma assets across oncology, neuroscience, rare diseases, and cardiometabolic disease, prioritizing compounds already in advanced clinical development or at commercial stage in China. The second pillar covers frontier technology incubation, with both parties exploring joint ventures or new entities designed to localize cutting-edge biotechnology within the UAE and build sovereign R&D capabilities. Modalities referenced include small molecules, biologics, radiopharmaceuticals, small interfering RNA therapies, and cell and gene therapies. The third pillar establishes a dedicated neuroscience collaboration targeting neurodegenerative diseases, with Alzheimer’s disease programs cited as a specific area of focus.
The work-share logic positions Fosun Pharma as the contributor of drug development capabilities, established technology platforms, and a pipeline built over more than 30 years of global R&D and manufacturing operations. Arcera contributes international market access infrastructure spanning more than 90 markets, along with manufacturing and packaging facilities across eight countries. The structure is designed to route Chinese biotech innovation through Abu Dhabi toward markets across the Middle East and beyond, with Arcera explicitly framed as a commercial and regulatory bridge.
Fosun Pharma’s platform portfolio, as described in the announcement, encompasses antibody-drug conjugate technology, small molecule programs, biologics, radiopharmaceuticals, small interfering RNA, and cell and gene therapy. The deal is described by Arcera as its first strategic partnership of this kind, and Fosun Pharma characterizes it as a step toward deepening international collaboration and expanding into global markets. The agreement is the first publicly announced collaboration between the two companies.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/